Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Status: Enrolling
Updated:  7/3/2012
Johns Hopkins Hospital
mi
from
Baltimore, MD
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
Status: Enrolling
Updated: 7/3/2012
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery
Mechanically-Manipulated Transrectal Ultrasound (TRUS) During Robotic-Assisted Laparoscopic Prostatectomy (RALP)
Status: Enrolling
Updated:  7/14/2012
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery
Mechanically-Manipulated Transrectal Ultrasound (TRUS) During Robotic-Assisted Laparoscopic Prostatectomy (RALP)
Status: Enrolling
Updated: 7/14/2012
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  7/16/2012
Pinnacle Oncology
mi
from
Scottsdale, AZ
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 7/16/2012
Pinnacle Oncology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  7/20/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 7/20/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  7/20/2012
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 7/20/2012
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  7/20/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 7/20/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  7/20/2012
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 7/20/2012
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Birmingham, AL
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Los Angeles, CA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 093
mi
from
Marina Del Rey, CA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 093
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
San Diego, CA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Fort Collins, CO
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 106
mi
from
Fort Myers, FL
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 106
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 094
mi
from
Port St Lucie, FL
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 094
mi
from
Port St Lucie, FL
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 096
mi
from
Atlanta, GA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 096
mi
from
Atlanta, GA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 103
mi
from
Baton Rouge, LA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 103
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 11
mi
from
Detroit, MI
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 11
mi
from
Detroit, MI
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 1021
mi
from
Rochester, MN
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 1021
mi
from
Rochester, MN
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 60
mi
from
Las Vegas, NV
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 60
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Cincinnati, OH
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 266
mi
from
Greensboro, SC
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 266
mi
from
Greensboro, SC
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 102
mi
from
Myrtle Beach, SC
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 102
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 084
mi
from
Memphis, TN
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 084
mi
from
Memphis, TN
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 1310
mi
from
Nashville, TN
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 1310
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
San Antonio, TX
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 059
mi
from
Tyler, TX
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 059
mi
from
Tyler, TX
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 047
mi
from
Newport, VA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 047
mi
from
Newport, VA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 104
mi
from
Norfolk, VA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 104
mi
from
Norfolk, VA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Seattle, WA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/9/2012
Tower Urology
mi
from
Los Angeles, CA
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/9/2012
Tower Urology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  8/9/2012
NorthShore University Health System
mi
from
Evanston, IL
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 8/9/2012
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
A Phase 1a/1b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  9/5/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
A Phase 1a/1b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients With Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 9/5/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Status: Enrolling
Updated:  9/11/2012
Progenics Pharmaceuticals, Inc.
mi
from
Tarrytown, NY
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Status: Enrolling
Updated: 9/11/2012
Progenics Pharmaceuticals, Inc.
mi
from
Tarrytown, NY
Click here to add this to my saved trials
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Status: Enrolling
Updated:  9/12/2012
Broadway Family Medicine Clinic
mi
from
Minneapolis, MN
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Status: Enrolling
Updated: 9/12/2012
Broadway Family Medicine Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
The Karmanos Cancer Institute
mi
from
Detriot, MI
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
The Karmanos Cancer Institute
mi
from
Detriot, MI
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
University of Wisconsin Madison, Carbone Cancer Center
mi
from
Madison, WI
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
University of Wisconsin Madison, Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Digoxin for Recurrent Prostate Cancer
A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA
Status: Enrolling
Updated:  11/6/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Digoxin for Recurrent Prostate Cancer
A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA
Status: Enrolling
Updated: 11/6/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
Status: Enrolling
Updated:  11/29/2012
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
Status: Enrolling
Updated: 11/29/2012
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
11C Acetate Imaging Post Prostatectomy
Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study
Status: Enrolling
Updated:  12/4/2012
Massachusetts General Hospital
mi
from
Boston, MA
11C Acetate Imaging Post Prostatectomy
Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study
Status: Enrolling
Updated: 12/4/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Status: Enrolling
Updated:  12/7/2012
Oncology Specialists, SC
mi
from
Park Ridge, IL
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Status: Enrolling
Updated: 12/7/2012
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Male Stress Urinary Incontinence and Sexual Health
Male Stress Urinary Incontinence and Sexual Health
Status: Enrolling
Updated:  12/11/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Male Stress Urinary Incontinence and Sexual Health
Male Stress Urinary Incontinence and Sexual Health
Status: Enrolling
Updated: 12/11/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC)Counts
Status: Enrolling
Updated:  1/3/2013
Massachusetts General Hospital
mi
from
Boston, MA
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC)Counts
Status: Enrolling
Updated: 1/3/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC)Counts
Status: Enrolling
Updated:  1/3/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC)Counts
Status: Enrolling
Updated: 1/3/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oral Colchicine in Men With Castrate Resistant Prostate Cancer
Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy
Status: Enrolling
Updated:  1/8/2013
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Oral Colchicine in Men With Castrate Resistant Prostate Cancer
Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy
Status: Enrolling
Updated: 1/8/2013
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
Status: Enrolling
Updated:  1/14/2013
Loma Linda University
mi
from
Loma Linda, CA
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
Status: Enrolling
Updated: 1/14/2013
Loma Linda University
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
Status: Enrolling
Updated:  1/14/2013
Kaiser Permanente
mi
from
Sacremento, CA
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
Status: Enrolling
Updated: 1/14/2013
Kaiser Permanente
mi
from
Sacremento, CA
Click here to add this to my saved trials
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
Status: Enrolling
Updated:  1/14/2013
Prostate Institute of America
mi
from
Ventura, CA
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
Status: Enrolling
Updated: 1/14/2013
Prostate Institute of America
mi
from
Ventura, CA
Click here to add this to my saved trials